International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 4 , Pages 974-977 , 15 March 2008

Radiation Retinopathy Is Treatable With Anti–Vascular Endothelial Growth Factor Bevacizumab (Avastin)

  • Paul T. Finger, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Paul T. Finger, M.D., The New York Eye Cancer Center, 115 East 61st Street, New York, NY 10065. Tel: (212) 832-8170; Fax: (212) 888–4030

Received 27 November 2007 ,Revised 30 November 2007 ,Accepted 30 November 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by The EyeCare Foundation, New York, NY.

 Presented in part at The American Academy of Ophthalmology Annual Meeting, November 12, 2007, New Orleans, LA.

 Conflict of interest: none.

PII: S0360-3016(07)04662-7

doi: 10.1016/j.ijrobp.2007.11.045

International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 4 , Pages 974-977 , 15 March 2008

Article Tools

* Image Usage & Resolution